SOLID TUMOURS

This study tests a new drug called ODM-212 in people with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more patients. About 315 adults with cancers like mesothelioma, lung, or co…

This study tests a new experimental drug called AZD4956, alone or with other cancer drugs, in people with advanced or metastatic solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the right dose, and see if the drug can …

This early-phase study tests a new drug, BI 3810944, in 69 adults with advanced solid tumors or melanoma who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously, usually every three w…

This study tests a new drug, BMS-986517, in adults with advanced solid tumors that have spread or cannot be removed. The main goal is to check safety and side effects, and also to see if the drug shrinks tumors. About 315 participants will take the drug alone, without other cance…

This early-stage study tests a new drug called AP601 in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the highest safe dose and check for side effects. About 36 participants will receive different doses based on body we…

This early-stage study is testing whether a shot of durvalumab given under the skin works as well as the standard IV infusion in adults with solid tumours. About 40 participants with various cancers will receive different doses to find the right amount and check safety. The goal …

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatments. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumo…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This early-stage study tests a new drug called RC220 given with a standard chemotherapy (doxorubicin) in adults with advanced solid tumors. The goal is to find a safe dose and see if RC220 can protect the heart from doxorubicin's side effects. About 53 people will take part.

This trial tests a drug called atezolizumab, already approved for some cancers, in people with rare cancers that have high numbers of genetic mutations or specific DNA repair problems. About 30 adults and children with these rare tumor types will receive the drug. The main goal i…

This study looks at three doses of olanzapine (2.5 mg, 5 mg, and 10 mg) to find the best balance between preventing nausea and vomiting from strong chemotherapy and reducing side effects like sleepiness. It will analyze data from about 2,000 adult patients with solid tumors. The …

This study collects leftover tissue and blood samples from 3,000 adults with solid tumors during routine care. Researchers will use advanced lab tests to find out why cancer cells spread and become resistant to treatments. The goal is to discover clues that could lead to better t…

This study is a registry that collects information from 15,000 adults with solid tumors who have had a genetic test (next-generation sequencing). The goal is to understand how genetic test results relate to treatments and patient outcomes over time. No new treatments are given; i…